STOP Using Corticosteroids in Cystic Fibrosis Pulmonary Exacerbations
The STOP (Standardized Treatment of Pulmonary Exacerbations) clinical studies were first described in 2017 (1 – 4). Initially designed as an observational study, they have evolved into a series of interventional studies designed to develop the best evidence base to inform pulmonary exacerbation (PEx) management, with the ultimate goal of using these data to ensure the best possible outcomes for affected persons with cystic fibrosis (pwCF) (2). STOP2, in particular, was a randomized trial primarily